// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Should new DVTs be managed by primary care? Audit of cancer screening for patients with newly diagnosed unprovoked DVT in a primary care setting

Y Raines - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Recurrent miscarriage and thrombophilia screening

E Phillips - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Protein C

A case of Klippel Trenaunay Syndrome in pregnancy

J Tam - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

N/A

Heparin

Effect of storage time on aPTT and impact on service provision

M Khan - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Diagnosis of pulmonary embolism in pregnancy

K Horspool - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Introducing a risk stratified protocol for outpatient management of patients with suspected pulmonary embolism in a district general hospital setting

J Griffin - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

rivaroxaban

Commutability – the importance of valid material for quality control in haemostasis

I Jennings - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Heparin

Measurement of rivaroxaban concentrations in blood using a range of assays

I Thom - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

rivaroxaban

Duration of hospitalisation following acute venous thromboembolism in routine care in England: an observational study using CPRD‐HES databases

R Alikhan - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Management of acquired haemophilia A in Royal London Hospital 2010–2015

A Zaidi - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cyclophosphamide

A review of management of acquired coagulopathy amongst hospital inpatients suggests superior correction of coagulopathy and better bleeding outcomes using prothrombin complex concentrate as compared with fresh frozen plasma

A Wood - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Prothrombin complex

An audit to investigate the use of age adjusted D‐dimers in the Bristol Royal Infirmary

L Carter-Brzezinski - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

N/A

N/A

A survey of National VTE Exemplar Centres’ investigation of Hospital‐Associated Thrombosis in 2014/15

L Roberts - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

Methadone hydrochloride

Audit of ‘Door to Needle’ time in administration of prothrombin complex concentrate to patients requiring urgent reversal of anticoagulation

S Elshafie - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

N/A

Prothrombin complex

The importance of probe washing in the protocols of automated haemostasis analysers and the perils of using manufacturer's target ranges for quality control

M Duncan - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

Heparin

Optimising oral anticoagulation in atrial fibrillation

L Corteville - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

Warfarin

Poor performance of a point of care D‐dimer test: UK NEQAS BC investigation and reporting to Medicines and Healthcare products Regulatory Agency (MHRA)

DP Kitchen - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Chronic deep vein thrombosis – is it more common than acute DVT?

S Musale - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

N/A

N/A

Efficacy and tolerability of first line steroid treatment in patients with immune thrombocytopenic purpura (ITP); real world data from a single centre

L Carter-Brzezinski - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

Dexamethasone

Portal vein thombosis – a different disease in the current era?

M Haris - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

Warfarin

Copyright © 2026. QuantiNova All rights reserved